disease biomarker
Recently Published Documents


TOTAL DOCUMENTS

290
(FIVE YEARS 111)

H-INDEX

36
(FIVE YEARS 8)

2021 ◽  
pp. 105054
Author(s):  
Daniele C.P. Rocha ◽  
Thiara Manuelle Alves Souza ◽  
Priscila Conrado Guerra Nunes ◽  
Ronaldo Mohana-Borges ◽  
Marciano V. Paes ◽  
...  

Author(s):  
Bradley J. Smith ◽  
Licia C. Silva-Costa ◽  
Daniel Martins-de-Souza

2021 ◽  
Author(s):  
Xiaoyan Liu ◽  
Xiaoyi Tian ◽  
Qinghong Shi ◽  
Haidan Sun ◽  
Jing Li ◽  
...  

Abstract Previous studies reported that gender, age, diets or lifestyles could influence urine metabolomics, which should be considered in biomarker discovery. As a consequence, for the baseline of urine metabolomics characteristics, it becomes critical to avoid confounding effects in clinical cohort studies. In this study, we provided a comprehensive characterization of urine metabolomics in a cohort of 348 healthy children (Aged 1~18) and 315 adults (Aged 20-78) for evaluation gender and age effects. Our results suggested that urine metabolites showed larger gender differences in children than in adults. For both male/boy and female/girl, each age group showed specific metabolic characterization. Especially, the pantothenate and CoA biosynthesis and alanine metabolism pathways were enriched in early life. Androgen and estrogen metabolism showed high activity during adolescence and youth stages. Pyrimidine metabolism was enriched in the old stage. This work could help us understand the baseline of urine metabolism characteristics and contribute to further studies of clinical disease biomarker discovery.


Author(s):  
Isabel J. Sible ◽  
Daniel A. Nation ◽  

AbstractBlood pressure variability is an emerging risk factor for dementia but relationships with markers of neurodegeneration and Alzheimer’s disease risk are understudied. We investigated blood pressure variability over one year and follow-up medial temporal brain volume change in apolipoprotein ϵ4 carriers and non-carriers, and in those with and without Alzheimer’s disease biomarker abnormality. 1051 Alzheimer’s Disease Neuroimaging Initiative participants without history of dementia or stroke underwent 3–4 blood pressure measurements over 12 months and ≥ 1 MRI thereafter. A subset (n = 252) underwent lumbar puncture to determine Alzheimer’s disease cerebral spinal fluid amyloid-beta and phosphorylated tau biomarker abnormality. Blood pressure variability over 12 months was calculated as variability independent of mean. Longitudinal hippocampal and entorhinal cortex volume data were extracted from serial brain MRI scans obtained after the final blood pressure measurement. Apolipoprotein ϵ4 carrier status was defined as at least one ϵ4 allele. Bayesian growth modelling revealed a significant interaction of blood pressure variability by ϵ4 by time on hippocampal (ß: -2.61 [95% credible interval -3.02, -2.12]) and entorhinal cortex (ß: -1.47 [95% credible interval -1.71, -1.17]) volume decline. A similar pattern emerged in subsets with Alzheimer’s disease pathophysiology (i.e., abnormal levels of both amyloid-beta and phosphorylated tau). Findings suggest that elevated blood pressure variability is related to medial temporal volume loss specifically in ϵ4 carriers, and in those with Alzheimer’s disease biomarker abnormality. Findings could implicate blood pressure variability in medial temporal neurodegeneration observed in older ϵ4 carriers and those with prodromal Alzheimer’s disease.


Sign in / Sign up

Export Citation Format

Share Document